Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma

Medical Oncology

Volumn 15, Issue 1, 1998, Pages 50-57

  Sparano, Joseph A ^a,c   Wiernik, Peter H ^a   Hu, Xiaoping ^a   Sarta, Catherine ^a   Henry, David H ^b   Ratech, Howard ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b GRADUATE HOSPITAL   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

AIDS associated lymphoma; Chemotherapy; Protease inhibitors; Saquinavir

Indexed keywords

CYCLOPHOSPHAMIDE; DIDANOSINE; DOXORUBICIN; ETOPOSIDE; PROTEINASE INHIBITOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SAQUINAVIR; STAVUDINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MIXTURE; DRUG POTENTIATION; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MUCOSA INFLAMMATION; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031808731     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02787345     Document Type: Article

References (24)

1. Rabkin CS, Yellin F. Cancer incidence in a population with a high prevalence of infection with human immunodeficiency virus type 1. Natl Cancer Inst 1994; 86: 1711-1716.
2. Gail MH et al. Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome. J Natl Cancer Inst 1991; 83: 695-700.
3. Pluda JM. et al. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol 1993; 11: 1099-1107.
4. Sparano JA. Treatment of AIDS-related lymphomas. Current Opinion in Oncology 1995; 7: 442-450.
5. Sparano JA et al. Infusional cyclophosphamide, doxorubicin, and etoposide in HIV- and HTLV-I-related non-Hodgkin's lymphoma: a highly active regimen. Blood 1993; 81: 2810-2815.
6. Sparano JA et al. Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: a follow up report of a highly active regimen. Leak Lymphoma 1994; 14: 263-271.
7. Sparano JA et al. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-related non-Hodgkin's lymphoma treated with chemotherapy: a case control study. J Natl Cancer Inst 1997; 89: 301-307.
8. Sparano JA. et al. A pilot trial of infusional cyclophosphamide, doxorubicin and etoposide plus didanosine and filgrastim in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 1996; 14: 3026-3035.
9. Litte R. et al. HIV viral burden during EPOCH chemotherapy for HIV-related lymphomas. J AIDS Human Retroviral 1997; 14:A42 (abstr 104).
10. Bartlett JG. Protease inhibitors for HIV infection. Ann Intern Med 1996; 124: 1086-1087.
11. Sparano JA, Sarta C. Infection prophylaxis and antiretroviral therapy in patients with HIV infection and malignancy. Curr Opin Oncol 1996; 8: 392-399.
12. Collier AC et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Eng J Med 1996; 334: 1011-1017.
13. Oken MM, Creech RH, Tormey DC. Toxicity and response criteria of the Eastern cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
14. Rosner B. Fundamentals of Biostatistics. 1995; 4th edn. Duxbury Press: New York.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
16. SAS/INSIGHT. User's Guide. 1993; 2nd edn, version 6. SAS Institute, Inc: Cary, NC.
17. Saquinavir (Invirase®) package insert. Roche Laboratories, Nutley, NJ, 07110. 1995.
18. Indinavir (Crixivan™) package insert. Merck & Co., West Point, PA, 19486. 1996.
19. Ritonavir (Norvir™) package insert. Abbot Laboratories, North Chicago, IL 60064. 1996.
20. Nelfinavir (Viracept®) package insert. Agouron Pharmaceuticals, Inc., La Jolla, CA, 92037. 1997.
21. Newman EM, Doroshow JH, Forman SJ, Blume KG. Pharmacokinetics of high-dose etoposide. Clin Pharmacol Ther 1998; 43: 561-564.
22. Jones RB et al. A Phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Oncol 1987; 5: 172-177.
23. Vogelzang N. Continuous infusion chemotherapy: a critical review. J Clin Oncol 1984; 2: 1289-1304.
24. Sparano JA et al. Infusional cyclophosphamide, doxorubicin, and etoposide for HIV-associated non-Hodgkin's lymphoma: long-term followup and analysis of prognostic factors. J AIDS Hum Retrovirol 1987; 14:A38 (abstr 88).